Ann: EMD-RX5 demonstrates excellent safety and bioavailability, page-22

will all due respect mate.

the market agrees with me right now, not you.

And i understand the 3 conditions

EPIDIOLEX is the first and only FDA-approved prescription cannabidiol (CBD) to treat seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of age or older.

got it........but we shouldnt have been promoting it has a key advantage, and game changer regarding bioavailability us Vs them, if it wasnt actually important., because EMD have created through that comparison, what the market is now reading as a miss Vs expectation and what they were hoping for.

Might not impact the long term future of the company, but when you go to market with that comparison of bioavailability as your key slide, and it doesn't translate. markets disappointed (hopefully short term, as they come to understand this better).

The company shouldnt have created a point of reference for success that wasnt important if it wasnt important or the market will punish you for that or at least not reward you, like we hoped.